An additional subcohort analysis restricted to the IDH-wild-type GBM cases also showed an independent impact of LEV treatment on OS (aHR = 0.64, 95% CI: 0.43–0.96, p = 0.032, see Table S3). The gene discussed is IDH1; the disease is glioblastoma.